1
Volker Rusch, Robert Reichhart, Michael Zeppezauer, Hans Jornvall: Biologically active substance with hormonal properties, production process thereof and utilization of histones for medical purposes. Volker Rusch, Weiser & Stapler, April 4, 1989: US04818763 (12 worldwide citation)

Biologically active substance with standardizable hormonal activity, containing in a physiological medium at least one histone, particularly at least one histone H2 or an active area of said histone with immune system immunostimulating and/or endocrinological properties. Utilization of histones and/ ...


2
Michael Zeppezauer, Robert Reichhart: Use of pure histones H1 and H2A:H2B dimers in therapeutic methods. Volker Rusch, Rosenman & Colin, January 26, 1993: US05182257 (9 worldwide citation)

The invention relates to the use of pure histones H1, H2A, H2B, H2A:H2B, H3 as hormonal or hormon-like active substance for the preparation of pharmaceuticals for the immuno-therapy, for the therapy of endocrine disturbance and for cancer therapy. Instead of the histones also their evolutionary vari ...


3
Michael Zeppezauer, Hans P Leinenbach: Cytostatic or cytotoxic combination of active substances for use in therapeutic procedures. Symbiotec Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie mbH, Kanesaka & Takeuchi, November 26, 1996: US05578571 (4 worldwide citation)

According to this invention the combination of active substances for use in therapeutic procedures consists of at least one cytostatic compound, e.g. vincristine, methotrexate, cisplatin as the first agent and at least one histone and/or one active histone fragment with cytostatic or cytotoxic activ ...


4
Reiner Class, Michael Zeppezauer: Antimicrobial histone H1 compositions, kits, and methods of use thereof. Symbiotec, Philadelphia Health and Education Corporation, Akin Gump Strauss Hauer & Feld, April 26, 2005: US06884423 (3 worldwide citation)

The invention includes antibiotic pharmaceutical compositions comprising eukaryotic histone H1 protein and methods of using eukaryotic histone H1 protein to kill or to inhibit the growth of microorganisms, including, but not limited to, human pathogenic bacteria. The invention further includes a euk ...


5
Michael Zeppezauer, Reiner Class: Therapeutic method for treatment of carcinoma or autoimmune diseases. Allegheny University of the Health Sciences, Kanesaka & Takeuchi, July 14, 1998: US05780432 (3 worldwide citation)

A therapeutic method for treatment of carcinoma or autoimmune diseases of a patient, which includes administering to said patient a biologically active composition which comprises a therapeutically acceptable carrier and, in a quantity having a therapeutic effect, two active substances comprising a ...


6
Michael Zeppezauer, Hans Peter Leinenbach, Reiner Class, Cordula Fassbender: Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties. Bacon & Thomas PLLC, March 8, 2011: US07902146 (2 worldwide citation)

A therapeutic or prophylactic agent for cancer is disclosed which damages the membrane and kills cancer cells, in particular of the blood-forming system, having membrane protein aggregates which contain several core histones or largely core-like histones and/or their parts. The therapeutic or prophy ...


7
Peter Gross, Hans Jornvall, Grazyna Formicka Zeppezauer, Michael Zeppezauer, Michel Thiry: Bis-met histones. Symbiotec Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie mbH, One3 IP Management P C, Annette S Parent, Dean G Stathakis, August 9, 2016: US09409960 (2 worldwide citation)

The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing s ...


8
Michael Zeppezauer, Arno Schönberger, Ladislav Cebecauer: Peptides for the production of preparations for the diagnosis and therapy of systemic lupus. Symbiotec Gesellschaft zur Erforschung und Entwicklung auf dem Gebiet der Biotechnologic mbH, Eugene C Raucidlo, Greenburg Traurig, April 9, 2002: US06369203 (1 worldwide citation)

Peptides are proposed with antigenic or immunogenic determinants, which result from autoantibodies in the body fluids of patients, who are suffering from systemic lupus erythematosus (SLE). In the case of the peptides it is preferably a question of the C terminus of H1 with the sequence section 187- ...


9
Reiner Class, Michael Zeppezauer: Use of histones for therapeutic purposes. Lipoxen Technologies Incorporated, One3 IP Management P C, Mary M H Eliason, Dean Stathakis, February 24, 2015: US08962562

The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.


10
Michael Zeppezauer, Peter Gross: Use of an active biological substance in abnormal cellular and viral membrane physiologies. Symbiotec Gesellschaft zur Forshung und Entwickling auf dem Gebiet der Biotechnologie mbH, One3 IP Management PC, Dean G Stathakis, Peter D Weinstein, July 15, 2014: US08778875

An active biological substance is disclosed for use in abnormal cellular and viral membrane physiologies in human and mammal organisms. The active substance has diagnostic and/or therapeutic properties and contains or consists of at least one component selected from the group of substances including ...



Click the thumbnails below to visualize the patent trend.